SAMIL PHARMACEUTICAL CO.,LTD
Financials
Valuation Metrics
SAMIL PHARMACEUTICAL CO.,LTD's Market Cap is ₩1614B. At end of 2025 it was ₩2102B. Ranked #924 of 2,405 in KR market (top 38%), #485 of 778 on KOSPI (top 62%), #107 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 46%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 161.39B KRW | KR#924/2,405 Sec#107/231 |
| Revenue | 207.33B KRW | KR#1,006/2,405 Sec#58/231 |
| Net Income | -37.61B KRW | KR—/2,405 Sec—/231 |
| Total Assets | 374.73B KRW | KR#911/2,405 Sec#54/231 |
| Net Assets | 125.55B KRW | KR#1,260/2,405 Sec#97/231 |
| Employees | 593 | KR#419/2,405 Sec#36/231 |
| Value | ||
| P/B | 1.29x | KR#1,724/2,405 Sec#117/231 |
| P/S | 0.78x | KR#1,271/2,405 Sec#69/231 |
| FCF Yield | -4.27% | KR—/2,405 Sec—/231 |
| Profitability | ||
| ROE | -29.96% | KR#2,170/2,405 Sec#173/231 |
| ROA | -10.04% | KR#2,095/2,405 Sec#159/231 |
| Op. Margin | -13.71% | KR#2,040/2,405 Sec#138/231 |
| Revenue Growth | -4.54% | KR#1,742/2,405 Sec#166/231 |
| Financial Health | ||
| Debt Ratio | 198.47% | KR#2,087/2,405 Sec#218/231 |
| Total Debt | 174.19B KRW | KR#553/2,405 Sec#30/231 |
| FCF | -6.89B KRW | KR#1,581/2,405 Sec#130/231 |
| Cash | 6.10B KRW | KR#1,924/2,405 Sec#173/231 |
| Current Ratio | 0.48x | KR#2,142/2,405 Sec#209/231 |
| Performance | ||
| 1Y Return | -21.68% | KR#1,150/2,405 Sec#81/231 |
| 1M Return | -13.49% | KR#1,450/2,405 Sec#147/231 |
| From 52W High | -42.15% | KR#835/2,405 Sec#59/231 |
| 1Y MDD | -52.64% | KR#1,073/2,405 Sec#88/231 |
| Trading | ||
| Volume | 46,450 shares | KR#1,020/2,405 Sec#111/231 |
| Trading Value | 347.2M KRW | KR#931/2,405 Sec#105/231 |
| Foreign Own. | 3.69% | KR#1,117/2,405 Sec#102/231 |
| Per Share | ||
| EPS | -1,734 KRW | KR—/2,405 Sec—/231 |
| BPS | 5,788 KRW | KR#1,392/2,405 Sec#99/231 |
Company Info
Samil Pharmaceutical, a mid-sized pharmaceutical company established in 1947 and listed on KOSPI in 1985, primarily develops, produces, and sells specialized and generic pharmaceuticals. The company also exclusively distributes directly imported original products in Korea. It operates a subsidiary with a global ophthalmic CDMO factory in Vietnam and has secured domestic sales rights for new drugs from Galmed and Biosplice. Samil Pharmaceutical is pursuing growth in new drug development and global CDMO business, headquartered in Seocho-gu, Seoul.